SRRK Stock Overview
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Scholar Rock Holding Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.23 |
| 52 Week High | US$21.17 |
| 52 Week Low | US$4.33 |
| Beta | 0.64 |
| 1 Month Change | 27.66% |
| 3 Month Change | 47.71% |
| 1 Year Change | -29.10% |
| 3 Year Change | -9.54% |
| 5 Year Change | n/a |
| Change since IPO | -21.10% |
Recent News & Updates
Recent updates
Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy
Oct 20Jay Backstrom is the new CEO at Scholar Rock
Sep 20Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology
Jul 12Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts
May 21
Broker Revenue Forecasts For Scholar Rock Holding Corporation (NASDAQ:SRRK) Are Surging Higher
Mar 08Scholar Rock Holding Corporation (NASDAQ:SRRK) Analysts Are More Bearish Than They Used To Be
May 15Is Scholar Rock Holding (NASDAQ:SRRK) Using Too Much Debt?
May 07If You Had Bought Scholar Rock Holding (NASDAQ:SRRK) Stock A Year Ago, You Could Pocket A 283% Gain Today
Mar 01We Think Scholar Rock Holding (NASDAQ:SRRK) Can Afford To Drive Business Growth
Jan 05
Scholar Rock EPS misses by $0.23, misses on revenue
Nov 09Scholar Rock Is At Phase 2, $1 Billion Is Too Expensive
Nov 04Scholar Rock prices ~$200M equity offering.
Oct 29Shareholder Returns
| SRRK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.3% | -0.3% | 1.7% |
| 1Y | -29.1% | 5.3% | -9.1% |
Return vs Industry: SRRK underperformed the US Biotechs industry which returned 3.9% over the past year.
Return vs Market: SRRK underperformed the US Market which returned -12.5% over the past year.
Price Volatility
| SRRK volatility | |
|---|---|
| SRRK Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: SRRK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: SRRK's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 145 | Jay Backstrom | https://scholarrock.com |
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis.
Scholar Rock Holding Corporation Fundamentals Summary
| SRRK fundamental statistics | |
|---|---|
| Market Cap | US$631.84m |
| Earnings (TTM) | -US$131.16m |
| Revenue (TTM) | US$37.24m |
17.0x
P/S Ratio-4.8x
P/E RatioIs SRRK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SRRK income statement (TTM) | |
|---|---|
| Revenue | US$37.24m |
| Cost of Revenue | US$13.91m |
| Gross Profit | US$23.33m |
| Other Expenses | US$154.49m |
| Earnings | -US$131.16m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.54 |
| Gross Margin | 62.64% |
| Net Profit Margin | -352.19% |
| Debt/Equity Ratio | 17.2% |
How did SRRK perform over the long term?
See historical performance and comparison